Baxter International
BAX
$26.73
-1.18%
Baxter International Inc. is a diversified healthcare company that manufactures and sells medical supplies and equipment, including injectable therapies, IV pumps, nutritional products, and surgical sealants, primarily to hospitals and care settings. The company operates in the Medical - Instruments & Supplies industry and has a significant market presence, with a portfolio expanded by the Hillrom acquisition in late 2021 and streamlined by the divestiture of its kidney care business in early 2025. Currently, the stock is gaining attention due to a recent earnings beat and raised guidance, which have driven a sharp rally, while investors debate the sustainability of its turnaround amid past operational challenges and supply chain disruptions.…
BAX
Baxter International
$26.73
Related headlines
Investment Opinion: Should I buy BAX Today?
Based on the analysis, Baxter is rated a Hold. The stock has shown strong recent momentum with a 19% weekly surge after a Q1 beat and raised guidance, but the average analyst target of $27.54 offers only 2% upside from the current price of $27.01. The forward P/E of 13.1x is attractive if the company can achieve estimated EPS of $2.16, but the negative trailing earnings and high debt levels temper enthusiasm. The recommendation consensus is 'hold', reflecting the mixed outlook.
Sign up to view all
BAX 12-Month Price Forecast
The AI assessment is neutral with medium confidence. Baxter's recent earnings beat and raised guidance are positive, but the company's high debt and inconsistent profitability create significant uncertainty. The forward valuation is reasonable, but the wide analyst target range and operational risks suggest a balanced risk-reward. To upgrade to bullish, Baxter would need to demonstrate sustained revenue growth above 5% and margin expansion. Conversely, a downgrade to bearish would be triggered by further operational disruptions or a failure to meet earnings estimates.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Baxter International's 12-month outlook, with a consensus price target around $28.73 and implied upside of +7.5% versus the current price.
Average Target
$28.73
0 analysts
Implied Upside
+7.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$23 - $40
Analyst target range
The target price range spans from a low of $19.00 to a high of $40.00, representing a wide spread of 110% from low to high, which signals high uncertainty about the company's future. The low target of $19.00 implies a potential downside of -29.7% from the current price, likely reflecting concerns about operational execution and margin pressure. The high target of $40.00 suggests an upside of +48.1%, which would require a successful turnaround and multiple expansion. Recent ratings actions show a mix: Citigroup downgraded to Sell in May 2026, while Barclays maintained Overweight, and Goldman Sachs and Evercore ISI have been consistent with Neutral and Outperform, respectively. This divergence in analyst views underscores the uncertainty around Baxter's recovery trajectory.
Bulls vs Bears: BAX Investment Factors
Baxter presents a classic turnaround story with recent positive momentum, but significant risks remain. The bull case is supported by the Q1 beat, raised guidance, and a reasonable forward valuation, while the bear case is anchored in persistent profitability issues, high leverage, and operational disruptions. Currently, the evidence slightly favors the bulls given the strong recent rally and improving fundamentals, but the wide analyst dispersion and negative trailing earnings create substantial uncertainty. The key tension is whether Baxter can sustain its operational improvements and translate them into consistent profitability, which would justify the current valuation and drive further upside.
Bullish
- Strong Q1 2026 beat and raised guidance: Baxter reported Q1 2026 revenue of $2,701 million, a 2.9% YoY increase, and raised its full-year guidance, driving a 19% weekly stock surge. This signals improving operational momentum and management confidence in the turnaround.
- Forward PE of 13.1x suggests undervaluation: With a forward P/E of 13.1x, the market is pricing in a significant earnings recovery, yet this multiple is below the typical healthcare sector average. If Baxter delivers on EPS estimates of $2.16, the stock offers substantial upside.
- Analyst average target implies 2% upside: The average analyst target of $27.54 is slightly above the current price of $27.01, indicating that analysts see modest upside. The high target of $40.00 suggests a potential 48% gain if the turnaround exceeds expectations.
- Low beta of 0.595 offers defensive characteristics: Baxter's beta of 0.595 means it is less volatile than the market, providing a defensive tilt. This is attractive for investors seeking stability in a healthcare portfolio, especially during economic uncertainty.
Bearish
- Negative trailing EPS and net margin: Baxter's trailing twelve-month EPS is -$0.10, and the net margin is -8.5%, reflecting persistent profitability challenges. The company has posted losses in several recent quarters, including a -$1.128 billion net loss in Q4 2025.
- High debt-to-equity ratio of 1.63: Baxter's debt-to-equity ratio of 1.63 indicates significant leverage, which increases financial risk. Interest expenses of $78 million in Q1 2026 weigh on earnings, and any further rate hikes could pressure the balance sheet.
- Wide analyst target range signals uncertainty: The analyst target range spans from $19.00 to $40.00, a 110% spread, reflecting deep disagreement about Baxter's future. The low target implies a -29.7% downside, highlighting execution risks.
- Manufacturing disruption and supply chain risks: Recent news of a manufacturing disruption affecting a cancer drug supply in Europe and rising petrochemical costs from the Strait of Hormuz could pressure margins and revenue. These operational issues may hinder the turnaround.
BAX Technical Analysis
Baxter's stock has experienced a volatile year, with a 1-year price change of +20.04%, but the path has been anything but smooth. The stock currently trades at $27.01, which is 90% of its 52-week range (low of $15.73, high of $30.00), indicating a strong recovery from the lows but still below the peak. This positioning suggests the stock is in a recovery phase, having rebounded significantly from its March 2026 trough, though it remains below the 52-week high, implying potential resistance overhead.
Beta
0.59
0.59x market volatility
Max Drawdown
-46.8%
Largest decline past year
52-Week Range
$16-$30
Price range past year
Annual Return
+9.3%
Cumulative gain past year
| Period | BAX Return | S&P 500 |
|---|---|---|
| 1m | +20.7% | +2.9% |
| 3m | +54.5% | +5.0% |
| 6m | +35.1% | +13.9% |
| 1y | +9.3% | +20.4% |
| ytd | +37.1% | +13.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BAX Fundamental Analysis
Baxter's revenue has shown modest growth, with the most recent quarter (Q1 2026) reporting revenue of $2,701 million, a 2.9% year-over-year increase. However, the multi-quarter trend is uneven: Q2 2025 revenue was $2,810 million, Q3 2025 was $2,835 million, and Q4 2025 was $2,974 million, indicating a slight deceleration in the latest quarter. The company's revenue segments show Medical Products and Therapies as the largest at $1,285 million, followed by Healthcare Systems and Technologies at $705 million and Pharmaceuticals at $621 million, but growth drivers are not clearly identified from the data.
Quarterly Revenue
$2.7B
2026-03
Revenue YoY Growth
+2.9%
YoY Comparison
Gross Margin
33.0%
Latest Quarter
Free Cash Flow
$714000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BAX Overvalued?
Given that Baxter's trailing twelve-month net income is negative (EPS of -$0.10), the price-to-earnings ratio is not meaningful, so I selected the price-to-sales (PS) ratio as the primary valuation metric. The trailing PS ratio is 0.87x, while the forward PE is 13.10x, implying the market expects a significant earnings recovery. The gap between the negative trailing earnings and positive forward earnings suggests the market is pricing in a turnaround, which is a key assumption to monitor.
PE
-10.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 20x~45x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are substantial. Baxter's trailing twelve-month net income is negative, with an EPS of -$0.10, and the net margin is -8.5%, indicating that the company is not yet consistently profitable. The debt-to-equity ratio of 1.63 highlights a heavy debt load, and interest expenses of $78 million in Q1 2026 consume a significant portion of operating income. Additionally, the gross margin has been volatile, dropping to 19.4% in Q4 2025 from 33.5% in Q3 2025, suggesting potential cost pressures. The company's free cash flow of $714 million is positive, but it may be insufficient to cover debt obligations and dividend payments if profitability does not improve.
FAQ
The key risks include financial risks from high debt (debt-to-equity of 1.63) and negative net margin (-8.5%), operational risks from manufacturing disruptions and supply chain issues, competitive risks from larger healthcare players, and macro risks from rising interest rates. The most severe risk is a failure to achieve the earnings recovery, which could lead to a decline toward the analyst low target of $19, a -29.7% downside.
The 12-month forecast is mixed. The base case (45% probability) sees the stock trading around $27.54, the average analyst target. The bull case (30% probability) targets $30-$40 if the turnaround exceeds expectations, while the bear case (25% probability) could see the stock fall to $19-$22 if operational issues persist. The most likely scenario is a gradual recovery with modest upside, but the wide target range reflects high uncertainty.
BAX appears fairly valued based on the average analyst target of $27.54, which is close to the current price of $27.01. The forward P/E of 13.1x is below the market average, suggesting potential undervaluation if earnings recover as expected. However, the trailing P/E is negative due to losses, and the price-to-sales ratio of 0.87x is in line with industry norms. The market is pricing in a successful turnaround, so the valuation is reasonable but not a bargain.
BAX is a hold for most investors. The stock has rallied 19% in a week after a strong Q1 beat, but the average analyst target of $27.54 offers only 2% upside from the current price. The forward P/E of 13.1x is attractive if the company achieves its EPS estimates, but the negative trailing earnings and high debt-to-equity ratio of 1.63 pose risks. For risk-tolerant investors with a long-term view, it could be a buy on dips, but for conservative investors, it's better to wait for more consistent profitability.
BAX is more suitable for long-term investment, given its turnaround nature and low beta of 0.595. Short-term trading is possible given the recent volatility, but the stock's recovery is uncertain. A minimum holding period of 12-18 months is recommended to allow the earnings recovery to materialize. The dividend yield of 3.55% provides some income while waiting, but the payout ratio is negative, indicating the dividend may be at risk if losses persist.